Intravitreal Ranibizumab for Stage IV Proliferative Sickle Cell Retinopathy: A First Case Report

Figure 3

(a–d) Fluorescein angiography, showing improvement of vitreous hemorrhage and slight regression of neovascularization, but presence of ischemic areas, one week after intravitreal ranibizumab injection; (e–h) fluorescein angiography, showing total absorption of vitreous hemorrhage, regression of neovascularization and ischemia at the periphery one month after intravitreal ranibizumab injection; (i–l) fluorescein angiography, showing laser photocoagulation spots in the previous ischemic areas, no recurrence of vitreous hemorrhage, and regression of neovascularization compared to baseline.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)